Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/12/2021 04/13/2021 04/14/2021 04/15/2021 04/16/2021 Date
100.53(c) 106.59(c) 107.97(c) 109.58(c) 108.72(c) Last
556 049 456 572 251 681 208 910 376 430 Volume
-2.85% +6.03% +1.29% +1.49% -0.78% Change
More quotes
Financials (USD)
Sales 2021 329 M - -
Net income 2021 -354 M - -
Net cash position 2021 813 M - -
P/E ratio 2021 -20,4x
Yield 2021 -
Sales 2022 414 M - -
Net income 2022 -324 M - -
Net cash position 2022 621 M - -
P/E ratio 2022 -24,2x
Yield 2022 -
Capitalization 7 279 M 7 279 M -
EV / Sales 2021 19,7x
EV / Sales 2022 16,1x
Nbr of Employees 893
Free-Float 94,7%
More Financials
Company
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.... 
More about the company
Notations Surperformance© of Ultragenyx Pharmaceutical Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ULTRAGENYX PHARMACEUTICAL INC.
04/16ULTRAGENYX PHARMACEUTICAL INC.  : Change in Directors or Principal Officers (for..
AQ
04/05N-LOREM FOUNDATION  : Partners with Ultragenyx to Bolster Development of Persona..
BU
03/08ULTRAGENYX PHARMACEUTICAL  : Receives FDA Clearance of Investigational NDA for U..
MT
03/08ULTRAGENYX PHARMACEUTICAL  : Announces FDA Clearance of Investigational New Drug..
AQ
03/03Ultragenyx to Present at Barclays Global Healthcare Conference
GL
03/02ULTRAGENYX PHARMACEUTICAL  : Stifel Reinstates Ultragenyx Pharmaceutical at Buy ..
MT
02/18ULTRAGENYX PHARMACEUTICAL  : Announces Approval of Dojolvi in Canada for the Tre..
AQ
02/17Ultragenyx to Present at Upcoming Investor Conferences
GL
02/17ULTRAGENYX PHARMACEUTICAL  : Obtains Canadian Approval of Dojolvi for Treatment ..
MT
02/17ULTRAGENYX PHARMACEUTICAL  : Announces Approval of Dojolvi™ (UX007/trihept..
AQ
02/16ULTRAGENYX PHARMACEUTICAL  : SVB Leerink Adjusts Ultragenyx Pharmaceutical's Pri..
MT
02/12ULTRAGENYX PHARMACEUTICAL  : Barclays Adjusts Ultragenyx Pharmaceutical PT to $1..
MT
02/12ULTRAGENYX PHARMACEUTICAL  : Piper Sandler Adjusts Ultragenyx Pharmaceutical PT ..
MT
02/12ULTRAGENYX PHARMACEUTICAL  : JPMorgan Downgrades Ultragenyx Pharmaceutical to Ne..
MT
02/12ULTRAGENYX PHARMACEUTICAL  : Wedbush Adjusts Price Target on Ultragenyx Pharmace..
MT
More news
News in other languages on ULTRAGENYX PHARMACEUTICAL INC.

- No features available -

More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations
Stock Trading Strategies
ULTRAGENYX PHARMACEUTICAL INC. - 2020
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 160,19 $
Last Close Price 108,72 $
Spread / Highest target 79,4%
Spread / Average Target 47,3%
Spread / Lowest Target -8,94%
EPS Revisions
Managers and Directors
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Mardi C. Dier Chief Financial Officer & Executive Vice President
Daniel G. Welch Non-Executive Chairman
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC.-21.46%7 279
GILEAD SCIENCES, INC.12.89%84 193
VERTEX PHARMACEUTICALS INCORPORATED-7.17%56 783
REGENERON PHARMACEUTICALS, INC.2.39%52 343
WUXI APPTEC CO., LTD.-0.05%50 466
BIONTECH SE85.89%36 600